The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate

Biomaterials

Volumn 35, Issue 19, 2014, Pages 5216-5225

  She, Zhennan ^a   Zhang, Ting ^a   Wang, Xuling ^a   Li, Xuan ^a   Song, Yanzhi ^a   Cheng, Xiaobo ^a   Huang, Zhenjun ^a   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Liposome pixantrone; Sialic acid octadecylamine conjugate; Tumor shed; Tumor associated macrophages

Indexed keywords

CARBOXYLIC ACIDS; LIPOSOMES; MACROPHAGES; MAMMALS; TOXICITY; TUMORS;

ANTICANCER EFFECTS; CANCEROUS TISSUES; CRITICAL ELEMENTS; DELIVERY VEHICLE; SIALIC ACID-OCTADECYLAMINE CONJUGATE; STEALTH LIPOSOMES; TUMOR DEVELOPMENT; TUMOR-ASSOCIATED MACROPHAGES;

LOADING;

LIPOSOME; OCTADECYLAMINE; PIXANTRONE; SIALIC ACID; AMINE; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; N ACETYLNEURAMINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; IMMUNE SYSTEM; LIFESPAN; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; WOUND HEALING; ANIMAL; CHEMISTRY; DRUG SCREENING; TUMOR CELL LINE; WISTAR RAT;

MUS;

AMINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ISOQUINOLINES; LIPOSOMES; MALE; MICE; N-ACETYLNEURAMINIC ACID; RATS; RATS, WISTAR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898421771     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.022     Document Type: Article

References (41)

1. Murrey H., Hsieh-Wilson L. The chemical neurobiology of carbohydrates. Chem Rev 2008, 108:1708-1731.
2. Wiederschain G.Y. Essentials of glycobiology. Biochem Mosc 2009, 74:1056.
3. Bondioli L., Ruozi B., Belletti D., Forni F., Vandelli M.A., Tosi G. Sialic acid as a potential approach for the protection and targeting of nanocarriers. Expert Opin Drug Deliv 2011, 1-17.
4. Turumi K.-I., Dawes S.M.L. Serum sialic acid levels in mice with neoplasms. Cancer Res 1958, 18:575-577.
5. Mabry E., Carubelli R. Sialic acid in human cancer. Cell Mol Life Sci 1972, 28:182-183.
6. Yogeeswaran G., Salk P. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 1981, 212:1514-1516.
7. Schauer R. Sialic acids as regulators of molecular and cellular interactions. Curr Opin Struct Biol 2009, 19:507-514.
8. Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008, 66:1-9.
9. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
10. Bingle L., Brown N., Lewis C. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002, 196:254-265.
11. Mantovani A., Schioppa T., Porta C., Allavena P., Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006, 25:315-322.
12. Mantovani A., Porta C., Rubino L., Allavena P., Sica A. Tumor-associated macrophages (TAMs) as new target in anticancer therapy. Drug Discov Today Ther Strateg 2006, 3:361-366.
13. Galdiero M.R., Garlanda C., Jaillon S., Marone G., Mantovani A. Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol 2013, 228:1404-1412.
14. Nath D., Hartnell A., Happerfield L., Miles D., Burchell J., Taylor-Papadimitriou J., et al. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 1999, 98:213-219.
15. Zheng J.S., Zheng S.Y., Zhang Y.B., Yu B., Zheng W., Yang F., et al. Sialic acid surface decoration enhances cellular uptake and apoptosis-inducing activity of selenium nanoparticles. Colloids Surf B 2011, 83:183-187.
16. Jayant S., Khandare J.J., Wang Y., Singh A.P., Vorsa N., Minko T. Targeted sialic acid-doxorubicin prodrugs for intracellular delivery and cancer treatment. Pharm Res 2007, 24:2120-2130.
17. Pean E., Flores B., Hudson I., Sjoberg J., Dunder K., Salmonson T., et al. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2013, 18:625-633.
18. Pixuvri: EPAR - summary for the public 2012, Lond United Kingdom.
19. Faivre S., Raymond E., Boige V., Gatineau M., Buthaut X., Rixe O., et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin Cancer Res 2001, 7:43-50.
20. Borchmann P., Schnell R., Knippertz R., Staak J., Camboni G., Bernareggi A., et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann Oncol 2001, 12:661-667.
21. Hong R.-L., Huang C.-J., Tseng Y.-L., Pang V.F., Chen S.-T., Liu J.-J., et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice is surface coating with polyethylene glycol beneficial?. Clin Cancer Res 1999, 5:3645-3652.
22. Forssen E.A., Tökes Z.A. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res 1983, 43:546-550.
23. Cell therapeutics, investigator's brochure for BBR2778 2002, Edition no. 6.
24. Ma Y., Yang Q., Wang L., Zhou X., Zhao Y., Deng Y. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. Eur J Pharm Scl 2012, 45:539-545.
25. Vliegenthart J.F.G., Dorland L., van Halbeek H., Haverkamp J.G. NMR spectroscopy of sialic acids. Sialic acids: chemistry, metabolism and function 1982, vol. 10:127-172. Springer, New York. S. Roland (Ed.).
26. Chang C., Barber L., Ouyang C., Masin D., Bally M., Madden T. Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. Br J Cancer 1997, 75:169.
27. Colombo R., Carotti A., Catto M., Racchi M., Lanni C., Verga L., et al. CE can identify small molecules that selectively target soluble oligomers of amyloid β protein and display antifibrillogenic activity. Electrophoresis 2009, 30:1418-1429.
28. Duggan S.T., Keating G.M. Pegylated liposomal doxorubicin. Drugs 2011, 71:2531-2558.
29. Cirstoiu-Hapca A., Buchegger F., Lange N., Bossy L., Gurny R., Delie F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 2010, 144:324-331.
30. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006, 66:6732-6740.
31. ®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001, 37:870-877.
32. Gajbhiye V., Ganesh N., Barve J., Jain N.K. Synthesis, characterization and targeting potential of zidovudine loaded sialic acid conjugated-mannosylated poly (propyleneimine) dendrimers. Eur J Pharm Scl 2013, 48:668-679.
33. Cukierman E., Khan D.R. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol 2010, 80:762-770.
34. Netti P.A., Berk D.A., Swartz M.A., Grodzinsky A.J., Jain R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497-2503.
35. Yoshikawa K., Mitsunaga S., Kinoshita T., Konishi M., Takahashi S., Gotohda N., et al. Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head. Cancer Sci 2012, 103.
36. Allavena P., Germano G., Marchesi F., Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011, 317:664-673.
37. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006, 3-15.
38. Sausville E.A., Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006, 66:3351-3354.
39. Gonsette R.E. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. J Neurol Sci 2004, 223:81-86.
40. Nishino M., Ashiku S.K., Kocher O.N., Thurer R.L., Boiselle P.M., Hatabu H. The thymus: a comprehensive review 1. Radiographics 2006, 26:335-348.
41. Cesta M.F. Normal structure, function, and histology of the spleen. Toxicol Pathol 2006, 34:455-465.